Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: Comparison of observed with predicted mortality

BMJ

Volumn 321, Issue 7262, 2000, Pages 665-669

  Blanks, R G ^a   Moss, S M ^a   Mcgahan, C E ^a   Quinn, M J ^b   Babb, P J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PREDICTION; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; ENGLAND; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN; WALES;

EID: 0034675228     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7262.665     Document Type: Article

References (20)

1. Forrest APM. Breast cancer screening: report to the health ministers of England, Wales, Scotland and Northern Ireland. London: HMSO, 1986.
2. Department of Health. The health of the nation: a strategy for health in England. London: HMSO, 1992.
3. Coleman MP, Babb P, Damiecki P, Groscalude P, Honjo S, Jones J, et al. Cancer survival trends in England and Wales 1971-1995: deprivation and NHS region. London: Stationery Office, 1999. (Studies in medical population subjects No 61.)
4. Moss S, Blanks R for the Interval Cancer Working Group. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS breast screening programme. J Epidemiol Community Health 1998; 52: 111–115.
5. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829–832.
6. Day NE, Williams DRR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 1989; 59: 954–958.
7. Quinn M, Allen E on behalf of the United Kingdom Association of Cancer Registries. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ 1995; 311: 1391–1395.
8. Duffy SW, Tabar L. Screening for breast cancer [letter]. Lancet 1996; 346: 852.
9. Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: earlier diagnosis or better treatment? BMJ 1997; 314: 472–475.
10. Department of Health and Welsh Office. A policy framework for commissioning cancer services. A report by the expert advisory group on cancer to the chief medical officer of England and Wales. London: Department of Health, 1995.
11. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I. Age-period and age-cohort models. Stat Med 1987; 6: 449–467.
12. Chouillet A, Bell CMJ, Hiscox J. Management of breast cancer in southeast England. BMJ 1994; 308: 168–171.
13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy. Lancet 1992; 339: 71–85.
14. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. Lyon: IARC, 1993 (Scientific publications No 121).
15. Langlands AO, Pocock SJ, Kerr GR, Gore SM. Long-tem survival of patients with breast cancer: a study of the curability of the disease. BMJ 1979; 2: 1247–1251.
16. Zahl PH, Tretli S. Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 1997; 16: 1435–1449.
17. Young KC, Wallis MG, Blanks RG, Moss SM. Influence of number of views and mammographic film density on the detection of invasive cancers: results from the NHS breast screening programme. Br J Radiol 1997; 70: 482–488.
18. Van den Akker-van Marle ME, de Koning H, Boer R, van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: comparison with the United Kingdom. J Med Screening 1999; 6: 30–34.
19. Peto R. Five years of tamoxifen—or more? [editorial]. J Natl Cancer Inst 1996; 88: 1791–1793.
20. NHS Breast Screening Programme. NHS BSP 1999 review. Sheffield: NHS BSP, 1999.